Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
12.53
+0.71 (6.01%)
At close: Nov 22, 2024, 4:00 PM
12.50
-0.03 (-0.24%)
After-hours: Nov 22, 2024, 7:57 PM EST
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$142,213
Profits / Employee
$5,297,557
Market Cap
9.12B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| The Ensign Group | 35,300 |
| Chemed | 15,087 |
| Teleflex | 14,500 |
| Bruker | 9,707 |
| Bio-Rad Laboratories | 8,030 |
| Masimo | 3,800 |
| Tempus AI | 1,952 |
| Repligen | 1,783 |
ROIV News
- 10 days ago - Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - GlobeNewsWire
- 4 weeks ago - Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility - Seeking Alpha
- 2 months ago - Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga
- 2 months ago - Roivant Flips a Skin Drug to Organon - Barrons
- 2 months ago - Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Business Wire
- 2 months ago - Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator - GlobeNewsWire
- 2 months ago - Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress - GlobeNewsWire